Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review

Cutler, Corey; Antin, Joseph H.

doi:10.1634/stemcells.19-2-108

Cited by 90 publications

(66 citation statements)

References 81 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CFU-GM techniques are also more laborious and prone to inter-laboratory differences. 2 These data further suggest that, in a fraction of MUD transplants, the PBPC product is likely 'damaged' relative to in vitro growth characteristics during the interval between collection and infusion. Additional support for this hypothesis derives from the results of second donations by two unrelated donors for patients at our center who had poor engraftment or no engraftment at all after their initial PBPC infusion.…”

Section: Discussionmentioning

confidence: 93%

“…Over the last decade, PBPCs have replaced BM as the preferred stem cell source in many programs. 1,2 Studies to compare the results of SCT with PBPCs and BM, with special attention to engraftment kinetics, GVHD and risk of recurrence of the underlying malignant disease have been performed for matched related donor (MRD) transplants 3,4 and are ongoing for matched unrelated donor (MUD) transplants. 5 The composition of the stem cell graft has a major influence on the engraftment kinetics after autologous PBPC transplantation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Slow platelet recovery after PBPC transplantation from unrelated donors

Jansen

Hanks

Akard

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

The effects of the composition of PBPC grafts from matched related donors (MRDs) and matched unrelated donors (MUDs) have not been compared. In a single-center study, the compositions of 55 MRD PBPC grafts and 33 MUD grafts were studied for their effect on the rate of engraftment in patients who had evidence of donor cell engraftment on day þ 28. The MUD grafts came more frequently from young male donors and contained more CD34 þ cells but similar numbers of colony-forming units granulocyte-macrophage (CFU-GM) and burst forming units-erythroid. The recovery of neutrophils to 4500/mm 3 was equally fast in both groups, but recovery of platelets to 420 000/mm 3 was significantly delayed in the MUD group (Po0.001). The MUD group also required more transfusions of platelets and red cells. Patients receiving grafts containing low numbers of CFU-GM had markedly delayed platelet recovery. The patients with the slowest engraftment tended to have prolonged transportation times. Storage experiments suggested a major loss of viable CD34 þ cells and CFU-GM when undiluted PBPC products are stored at room temperature. The data suggest that a fraction of the MUD grafts suffer during transportation. In vitro proliferation assays should be part of the validation and auditing of transportation of MUD grafts.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Slow platelet recovery after PBPC transplantation from unrelated donors

Jansen

Hanks

Akard

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The specific biological factors leading to a more rapid engraftment are yet to be identified fully and represent a gap in the basic understanding of stem cell biology. 8 With the introduction of PBSC as a substitute for BM in many cases, it was realized that there are important phenotypic and biologic distinction between them; the former is claimed to be associated with more rapid engraftment. [9][10][11][12] These considerations make it essential to evaluate, properly, the engraftment potential especially in case of PBSCT.…”

Section: Discussionmentioning

confidence: 99%

“…13 The relative importance of subsets may be more evident when low numbers of CD34 þ cells are infused; the presence of higher numbers of CD34 þ /CD33À or CD34 þ /CD38À cells predicts early neutrophil engraftment. 20,40 For platelet recovery, total CD34 þ cell dose was recognized as a predictor as well as the following subsets: 13,37 Platelet recovery has been reported to be more sensitive to CD34 þ dose than neutrophil recovery; 8,41 the threshold dose to achieve rapid platelet recovery varied between 5 Â 10 6 /kg [42][43][44][45] and 15 Â 10 6 /kg. 46 Patients who received 45 Â 10 6 CD34 þ cells/kg required significantly fewer platelet units, 45 shorter duration of antibiotic therapy 45,47 and shorter hospital stay.…”

Section: Discussionmentioning

confidence: 99%

Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation

Kamel

El-Sharkawy

Mahmoud

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Our objective was to evaluate, probably for the first time, the impact of CD34 subsets on engraftment kinetics in allogeneic PBSC transplantation (PBSCT). PBSC graft components were analyzed in 62 cases for the absolute count/kg of total CD34 þ and the following subsets: DRÀ and þ , CD71 þ /À, CD38þ /À, CD33þ /À and CD61 þ /À. Time to ANC 40.5 and 41 Â 10 9 /l and platelets 420 and 450 Â 10 9 /l was reported. The median value for each parameter was used to discriminate rapid from slow engraftment. Four parameters showed significant predictive power of early neutrophil engraftment, namely CD34 þ / DRÀ (P ¼ 0.002), CD34 þ /38À (P ¼ 0.02), CD34 þ / CD61À (P ¼ 0.04) and total CD34 þ cell dose (P ¼ 0.04). Four parameters showed significant predictive power of early platelet engraftment, namely CD34 þ /CD61 þ (P ¼ 0.02), CD34 þ /CD38À and total CD34 þ cell dose (P ¼ 0.04) and CD34 þ /CD71À (P ¼ 0.05). Comparing patients who received 4to those who received o the threshold dose(s), only CD34 þ /CD38À lost its significance for neutrophil engraftment; and only CD34 þ /CD61 þ retained its significance for platelet engraftment (P ¼ 0.03); furthermore, the former group required significantly fewer platelet transfusions (P ¼ 0.018). We concluded that in allogeneic PBSCT, the best predictor of early neutrophil engraftment is the absolute CD34 þ /DRÀ and for early platelet engraftment is the absolute CD34 þ /CD61 þ cell dose.

show abstract

“…It is logical that progenitor cells circulate in the periphery, as this ensures an even distribution of hematopoiesis within the BM [7]. CD34 antigen expression is used as a surrogate marker for hematopoietic stem cells and enumeration of CD34 + cells has been used to quantify progenitor and stem cell content [8].…”

Section: Characterization Of Hematopoietic Stem Cellsmentioning

confidence: 99%

Hematopoietic stem cells from peripheral blood the perspective of non-mobilized peripheral blood

Katsares¹,

Paparidis²,

Nikolaidou³

et al. 2010

Health

View full text Add to dashboard Cite

The peripheral blood is a major source of hematopoietic stem cells. Almost for two decades the peripheral blood has been mobilized, in order to enhance the CD34 + concentration. The isolated stem cells from the mobilized peripheral blood are used as an alternative, or in addition to bone marrow derived stem cells. In this paper, a new perspective is being discussed; the use of non-mobilized peripheral blood as an alternative source for hematopoietic progenitor cells. The number of isolated hematopoietic stem cells is evaluated using flow cytometry. The viability can be evaluated using the trypan blue exclusion test, the flow cytometry or automated assays. The isolated hematopoietic stem cells could be used for ex vivo expansion either in static systems or in proper bioreactor systems, prior to cryopreservation and/or transplantation.

show abstract

Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review

Abstract: ABSTRACT

Cited by 90 publications

References 81 publications

Slow platelet recovery after PBPC transplantation from unrelated donors

Slow platelet recovery after PBPC transplantation from unrelated donors

Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation

Hematopoietic stem cells from peripheral blood the perspective of non-mobilized peripheral blood

Contact Info

Product

Resources

About